Search
Search
Editorially independent content, supported with advertising
03.24.22
Have innovations in therapy actually led to a paradigm shift when it comes to encountering patients with newly diagnosed wet AMD? In the season finale of “The Art of Drug Choice,” moderator Arshad M. Khanani, MD, MA, is joined by panelists Lejla Vajzovic, MD, and Joseph M. Coney, MD, to review strategies for treating new wet AMD patients, to discuss where new technologies fit into a treatment algorithm, and to examine the best time to switch patients to a new therapeutic option. After the break, Dr. Khanani updates the panel on a patient case shared in previous seasons of this series, which involves a patient with a 12-year treatment history who experienced significant vision loss following a change in therapy. How did Dr. Khanani manage the case—and what happened after inflammation was brought under control? This editorially independent podcast is supported with advertising.
Editorially Independent content supported by Novartis & Alcon.
03.24.22
Art of Drug Choice: Treating New Wet AMD PatientsArshad M. Khanani, MD, MA; Lejla Vajzovic, MD, and Joseph M. Coney, MD
Editorially Independent content supported by Novartis & Alcon.
03.17.22
Art of Drug Choice: Who Is Best Suited for Extended-duration Therapy?Arshad M. Khanani, MD, MA; Lejla Vajzovic, MD; and Joseph M. Coney, MD
Editorially Independent content supported by Novartis & Alcon.
03.03.22
Art of Drug Choice: The Latest Advances in Wet AMD TherapyArshad M. Khanani, MD, MA; Lejla Vajzovic, MD, and Joseph M. Coney, MD
Editorially Independent content supported by Novartis & Alcon.
09.10.21
The Art of Drug Choice: International Panel in Wet AMD: Safety DataArshad M. Khanani, MD; Justus G. Garweg, MD; Seenu M. Hariprasad, MD; Peter Kertes, MD, FRCSC
09.01.21
The Art of Drug Choice: International Panel in Wet AMD: The PipelineArshad M. Khanani, MD; Justus G. Garweg, MD; Seenu M. Hariprasad, MD; Peter Kertes, MD, FRCSC
08.20.21
The Art of Drug Choice: International Panel in Wet AMD: Phase 3 and Real-World Data to WatchArshad Khanani, MD, MA; Justus Garweg, MD; Seenu Hariprasad, MD; Peter Kertes, MD, FRCSC
08.06.21
The Art of Drug Choice: International Panel in Wet AMD: When and Why Switching Therapy Makes SenseArshad M. Khanani, MD, MA; Justus G. Garweg, MD; Seenu M. Hariprasad, MD; and Peter Kertes, MD, FRCSC
11.19.20
The Art of Drug Choice: Safety in Wet AMDArshad M. Khanani, MD, MA; Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA
11.19.20
The Art of Drug Choice: Wet AMD PipelineArshad M. Khanani, MD, MA; Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA
11.19.20
The Art of Drug Choice: Phase 3 Trials in Wet AMDArshad M. Khanani, MD, MA; Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA
